Hematopoietic stem cell proliferating agents

Patent Number: 7037892

Stimulation of hematopoiesis in patients who are neutropenic after chemo, or radiation is a major goal of medicine. This is particularly important due to infectious disease complications that arise in patients that have been myeloablated. This patent teaches the use of insulin like growth factor as an adjuvant to several of the major stimulators of hematopoiesis that are already in the clinic. Additionally, IFG-1 already approved clinically under the name mecasermin. The patent has 1 independent claim which a method of stimulating proliferation of hematopoietic stem cells through using IFG-1 together with either M-CSF or G-CSF.

View this patent on the USPTO website.